Charles River Laboratories International, Inc. ( CRL ) Nowojorska Giełda Papierów Wartościowych

Cena: 161.56 ( 4.55% )

Aktualizacja 08-22 21:59
Nowojorska Giełda Papierów Wartościowych
Branża: Medical - Diagnostics & Research
Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Charles River Laboratories International, Inc., niekliniczna organizacja badań kontraktowych, zapewnia usługi odkrywania leków, rozwoju nieklinicznego i testowania bezpieczeństwa w Stanach Zjednoczonych, Europie, Kanadzie, Azji i Pacyfiku i na arenie międzynarodowej. Działa w trzech segmentach: modele i usługi badawcze (RMS), ocena odkrywania i bezpieczeństwa (DSA) oraz rozwiązania produkcyjne (produkcja). Segment RMS produkuje i sprzedaje szczepy modelu badań gryzoni oraz wyżywione przez cel szczury i myszy do użytku przez naukowców. Ten segment zapewnia również szereg usług, które pomagają swoim klientom w wspieraniu stosowania modeli badawczych w badaniach i badaniach nieklinicznych kandydatów na leki, w tym modele badawcze, genetycznie zmodyfikowane modele i usługi, rozwiązania insourcingowe i badania diagnostyki zwierząt badawczych. Segment DSA oferuje wczesne i in vivo usługi odkrywania w celu identyfikacji i walidacji nowych celów, związków chemicznych i przeciwciał poprzez dostarczanie nieklinicznych kandydatów na leki i terapeutyczne gotowe do oceny bezpieczeństwa; oraz usługi oceny bezpieczeństwa, takie jak toksykologia, patologia, farmakologia bezpieczeństwa, bioanaliza, metabolizm leków i usługi farmakokinetyczne. Segment produkcyjny zapewnia metody in vitro do konwencjonalnego i szybkiego testowania kontroli jakości sterylnych i niesterycznych produktów farmaceutycznych i produktów konsumenckich. Ten segment oferuje również wyspecjalizowane testy biologiczne, które są zlecane przez firmy farmaceutyczne i biotechnologiczne; oraz ptasie usługi szczepionek, które zapewniają żyzne jaja kurczaka bez patogenu (SPF), kurczaki SPF i produkty diagnostyczne stosowane do produkcji szczepionek. Firma świadczy również usługi operacyjne Vivarium dla klientów biofarmaceutycznych. Charles River Laboratories International, Inc. został założony w 1947 roku i ma siedzibę w Wilmington w stanie Massachusetts.

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Diagnostics & Research
Zatrudnienie: 20 400
Giełda: Nowojorska Giełda Papierów Wartościowych
Ilość akcji w obrocie: 97.8292
Ilość akcji: Brak danych
Debiut giełdowy: 2000-06-23
WWW: https://www.criver.com
CEO: Mr. James C. Foster J.D.
Adres: 251 Ballardvale Street
Siedziba: 01887 Wilmington
ISIN: US1598641074
Wskaźniki finansowe
Kapitalizacja (USD) 7 951 292 223
Aktywa: 8 003 842 000
Cena: 161.56
Wskaźnik Altman Z-Score: 2.6
Umiarkowany (ryzyko bankructwa średnie)
Dywidenda: 0
P/E: -125.2
Ilość akcji w obrocie: 98%
Średni wolumen: 895 650
Ilość akcji 49 214 200
Wskaźniki finansowe
Przychody TTM 4 060 916 000
Zobowiązania: 4 176 125 000
Przedział 52 tyg.: 91.86 - 230.02
Piotroski F-Score: 6
Umiarkowany (średnia jakość finansowa)
EPS: -1.3
P/E branży: 31.3
Beta: 1.376
Raport okresowy: 2025-11-05
WWW: https://www.criver.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Joseph W. LaPlume Corporate Executive Vice President of Corporate Development & Strategy 928 357 1974
Mr. James C. Foster J.D. Chief Executive Officer, President & Chairman 2 663 827 1951
Ms. Flavia H. Pease Corporate Executive Vice President & Chief Financial Officer 1 656 005 1973
Ms. Birgit Girshick Corporate Executive Vice President & Chief Operating Officer 1 280 523 1970
Mr. William D. Barbo Corporate Executive Vice President of Community Relations 1 004 066 1961
Mr. Michael Gunnar Knell Corporate Senior Vice President & Chief Accounting Officer 0 1977
Mr. Mark Mintz Corporate Senior Vice President & Chief Information Officer 0 0
Todd Spencer Corporate Vice President of Investor Relations 0 0
Mr. Matthew L. Daniel Corporate Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer 0 0
Prof. Julie Frearson Ph.D. Corporate Senior Vice President & Chief Scientific Officer 0 0
Lista ETF z ekspozycją na akcje Charles River Laboratories International, Inc.
Symbol ETF Ilość akcji Wartość
SCYB 1 541 000 1 479 659
VOO 1 394 552 211 595 374
VB 1 200 199 182 106 194
JCPB 1 095 000 1 004 827
RSP 934 983 164 734 654
XHY.TO 785 000 1 040 630
VBR 765 760 116 188 764
IVV 606 605 102 904 474
SPY 597 176 105 574 217
FSYD 583 000 566 957
SIHY 550 000 503 827
BBHY 416 000 381 742
XLV 336 578 59 387 942
IBB 308 348 52 308 168
IEFA 227 340 6 172 326
GHYB 215 000 198 622
BBHY 183 000 177 392
IWR 179 102 30 382 908
GSPX.L 162 872 20 912 343
VHT 152 991 23 213 324
XDEW.DE 146 694 21 792 014
XDEW.L 146 694 24 885 251
XDWE.L 146 694 1 885 779 495
XEWG.L 146 694 18 857 794
XDEE.DE 146 694 21 792 014
DFAS 132 457 22 470 005
SCHM 130 643 22 766 913
CSP1.L 123 275 15 828 134
CSPX.L 123 275 20 912 343
CSSPX.MI 123 275 18 294 118
CSPX.AS 123 275 18 294 118
SXR8.DE 123 275 18 294 118
IWD 111 525 18 919 106
WTV 96 080 16 299 011
SCHC 83 736 2 265 475
IVE 81 675 13 855 405
ISPE.L 79 736 10 237 872
RSPH 78 240 13 785 105
IWS 75 310 12 775 536
SCHG 75 162 13 239 739
SPLG 71 843 12 662 912
VUSD.L 66 178 10 041 187
VUAA.L 66 178 10 041 187
VUSA.AS 66 178 8 793 068
VUSA.MI 66 178 8 793 068
VUAA.MI 66 178 8 793 068
VUSA.DE 66 178 8 793 068
VUSA.L 66 178 7 609 111
HEAL.L 62 626 10 623 904
DRDR.L 62 626 8 041 020
2B78.DE 62 626 9 293 791
ITOT 62 511 10 604 347
DFSV 61 563 10 443 547
EWSP.L 60 351 7 748 840
FNDA 56 408 9 815 597
SPYV 53 629 9 502 141
SCHX 49 381 8 671 608
BBHY 43 000 40 506
FMDE 41 970 7 512 210
DFUV 41 477 7 036 158
IUSV 41 164 6 983 114
NEAR 40 000 39 268
JHMM 39 806 5 695 442
DFAC 37 513 6 363 705
IWB 36 552 6 200 654
BBH 34 424 5 839 687
IXJ 28 757 4 878 348
SCHB 28 240 4 956 866
IYH 28 102 4 767 172
SP5A.MI 27 371 4 223 060
SPYL.L 27 371 4 822 496
SPY5.PA 27 371 4 223 060
SPPE.DE 27 371 4 822 496
SPY5.DE 27 371 4 223 060
SPXE.MI 27 371 4 822 496
SPX5.L 27 371 3 654 439
SPY5.L 27 371 4 822 496
IUHE.AS 26 681 3 959 517
SCZ 26 626 4 516 815
VONV 24 627 3 736 654
SXRG.DE 24 443 3 627 319
CUSS.L 24 443 4 146 455
CUS1.L 24 443 3 138 369
CSUSS.MI 24 443 3 627 319
SPHB 23 735 4 181 869
IUHC.L 23 341 3 959 517
IHCU.L 23 341 2 996 879
QDVG.DE 23 341 3 463 786
BBMC 21 340 3 620 117
ESML 21 302 3 753 199
FHLC 20 818 3 726 213
XBB 20 000 0
XBB 20 000 0
IUSA.DE 18 504 2 745 998
IUSA.L 18 504 2 375 847
IUSA.AS 18 504 2 745 998
IDUS.L 18 504 3 139 001
SXRJ.DE 15 020 2 228 917
CES1.L 15 017 1 928 103
RECS 14 333 2 431 450
IWV 14 198 2 408 517
XEF.TO 13 685 513 129
FNDX 13 409 2 349 957
BINC 12 986 2 202 973
DHYG.L 11 851 1 521 638
SMMD 11 485 2 023 542
VOOV 11 430 1 734 273
DHYC.SW 11 038 1 521 638
DHYG.L 10 982 1 410 014
DHYG.L 10 708 1 374 908
ESGV 10 620 1 611 372
SPPY.DE 10 468 1 615 103
500X.AS 10 468 1 615 103
UEEF.DE 10 254 1 521 638
DHYC.SW 10 228 1 410 014
DHYC.SW 9 973 1 374 908
EZM 9 895 1 678 587
UEEF.DE 9 501 1 410 014
SPTM 9 286 1 638 811
UEEF.DE 9 265 1 374 908
DFAU 9 042 1 533 884
DHYA.L 8 970 1 521 638
DHYD.AS 8 970 1 521 638
DHYE.AS 8 970 1 331 129
RWL 8 601 1 515 410
XSP.TO 8 338 2 028 869
DHYA.L 8 312 1 410 014
DHYD.AS 8 312 1 410 014
DHYE.AS 8 312 1 233 480
KOMP 8 175 1 443 932
IBCF.DE 8 169 1 212 303
IUSE.L 8 169 1 212 303
DHYE.AS 8 105 1 202 769
DHYD.AS 8 105 1 374 908
DHYA.L 8 105 1 374 908
PRF 8 050 1 418 329
TILT 7 852 1 332 013
F500.DE 7 803 1 210 787
S500H.PA 7 803 1 210 787
S500.PA 7 803 1 210 787
S500.MI 7 803 1 210 787
VONE 7 581 1 150 265
IDEV 7 132 1 209 812
CSH2.L 6 948 93 744 802
EGV2.DE 6 948 1 083 579
SMTC.L 6 948 1 237 068
CSH2.PA 6 948 1 083 579
HTEC 6 885 0
IVV.AX 6 830 1 862 454
HYSD.L 6 540 839 677
LSK7.DE 6 465 992 219
BSX.PA 6 465 992 219
VFVA 6 429 975 472
XUS.TO 6 362 1 548 149
IXJ.AX 6 297 1 717 177
ZPRV.DE 6 227 836 900
USSC.L 6 227 955 692
ALTL 5 848 992 054
ACWI.PA 5 688 872 969
LYY0.DE 5 688 872 969
ACWL.L 5 688 75 524 063
ACWU.L 5 688 996 625
HYSD.L 5 616 721 015
IUSN.DE 5 425 805 039
WSML.L 5 425 920 256
WLDS.L 5 425 696 523
IEUR 5 363 909 776
5ESG.L 5 255 937 843
IQSM 5 117 868 047
HYSD.L 5 109 655 942
SSO 5 005 849 048
HYUS.L 4 950 839 677
HYUS.SW 4 950 839 677
SMLF 4 604 781 050
5ESGE.MI 4 560 813 646
S5SG.DE 4 560 813 646
BINC 4 356 739 013
HYUS.L 4 250 721 015
HYUS.SW 4 250 721 015
RSPA 4 028 709 693
S5SD.DE 3 993 712 592
HYUS.L 3 867 655 942
HYUS.SW 3 867 655 942
EQAL 3 857 679 564
VTHR 3 773 572 477
SCHK 3 693 648 372
SPXL 3 407 577 963
PSET 3 274 555 401
ZPDH.DE 3 251 501 595
SXLV.L 3 251 572 793
PTLC 3 190 541 151
XYLD 3 099 525 714
SNPE 2 864 504 608
IHHG.L 2 627 337 346
XHC.TO 2 540 617 955
SAEF 2 513 393 715
UPRO 2 429 412 055
SPUS 2 359 400 180
XUU.TO 2 297 558 829
IHYE.L 2 273 337 346
IBC2.DE 2 273 337 346
IYY 2 270 385 151
IHHG.L 2 228 286 035
SPYX 2 186 385 554
USPG.L 2 165 381 403
ISCB 2 164 367 179
XEU.TO 2 074 77 766
HIBL 2 064 350 136
IHYA.L 1 989 337 346
SHYU.L 1 989 255 330
IS0R.DE 1 989 295 110
IHYU.MI 1 989 295 110
IHYU.L 1 989 337 346
FTXH 1 987 324 596
XFH.TO 1 952 73 212
IHYE.L 1 927 286 035
IBC2.DE 1 927 286 035
VOOM.DE 1 907 292 116
ELLE.L 1 907 333 494
GEND.L 1 907 252 721
UEQD.DE 1 878 330 895
JHML 1 801 257 687
AVUS 1 759 309 918
GHYG.L 1 740 223 425
GUSA 1 725 274 223
IHYU.L 1 686 286 035
IS0R.DE 1 686 250 224
IHYU.MI 1 686 250 224
SHYU.L 1 686 216 494
IHYA.L 1 686 286 035
GHYG.L 1 671 214 526
IHVV.AX 1 658 452 056
XDPU.L 1 649 279 789
XDPD.DE 1 649 245 011
IE000Z9SJA06.SG 1 649 245 011
XDPC.SW 1 649 227 810
XDPE.DE 1 649 245 011
XDPG.L 1 649 21 202 185
UBU9.DE 1 645 289 798
UC13.L 1 645 289 798
HYLC.SW 1 621 223 425
HYLC.SW 1 556 214 526
HYLE.DE 1 506 223 425
100H.PA 1 490 228 678
100H.L 1 490 261 070
EFIV 1 490 263 037
100D.L 1 490 19 783 905
L100.L 1 490 19 783 905
HYLE.DE 1 446 214 526
QVML 1 380 243 142
DX2D.DE 1 345 199 825
XLPE.L 1 345 17 287 678
HYLA.L 1 317 223 425
IBC9.DE 1 317 195 452
HYLD.L 1 317 223 425
IGHY.L 1 317 169 106
HYLA.L 1 265 214 526
IBC9.DE 1 265 187 668
HYLD.L 1 265 214 526
IGHY.L 1 265 162 371
C024.DE 1 246 191 230
CURE 1 221 207 130
EWSA.AS 1 190 201 913
CBUG.DE 1 190 176 634
IGUS.L 1 171 150 332
IUS 1 162 204 732
IS3K.DE 1 124 166 822
SDHG.L 1 124 144 335
SDHY.L 1 124 190 698
SDHA.L 1 124 190 698
HELX 1 089 191 870
IS3K.DE 1 041 154 426
SDHG.L 1 041 133 609
SDHY.L 1 041 176 527
SDHA.L 1 041 176 527
VE.TO 1 039 37 610
GHYG.L 1 039 133 369
FNDB 1 027 179 749
GPIX 1 001 159 128
CBUM.DE 985 146 237
HYLC.SW 967 133 369
AVMC 953 167 909
XEH.TO 924 34 639
HYLE.DE 899 133 369
QDPL 880 149 283
RSPE 865 152 404
ESPX.AS 862 146 237
SZNE 862 146 229
IUSC.SW 850 117 148
LSEQ 844 148 704
V3AL.L 829 125 784
V3AB.L 829 95 317
V3AA.L 829 125 784
IEUS 824 139 796
ISPY 812 137 747
S5SD.L 791 141 133
HYLA.L 786 133 369
IBC9.DE 786 116 671
HYLD.L 786 133 369
IGHY.L 786 100 944
DXUV 766 129 944
V3AA.L 762 20 215
V3AB.L 762 15 318
V3AL.L 762 20 215
SPYI 705 112 377
REVS 699 118 578
DFLV 677 114 846
GVUS 627 99 674
XWD.TO 604 146 922
VLU 584 103 475
VVL.TO 571 118 217
RXL 518 87 873
JUST 471 74 874
IHHY.AX 452 65 626
XVV 428 75 409
R1VL.L 421 71 356
DBEZ 413 11 157
HCMT 365 61 918
XBAL.TO 347 84 515
BMED 343 58 142
XUH.TO 339 59 734
XBAL.TO 337 12 622
AMEQ.DE 312 47 884
QCEU.PA 312 47 884
USFM.L 289 50 883
USUE.DE 289 50 883
SPXT 288 48 856
AVLC 282 49 685
XTR.TO 267 35 017
PBP 262 46 161
IHHG.L 254 32 582
STXM 251 42 579
IHYE.L 220 32 582
IBC2.DE 220 32 582
IHYU.L 192 32 582
IS0R.DE 192 28 503
IHYU.MI 192 28 503
SHYU.L 192 24 661
IHYA.L 192 32 582
AVSU 188 33 123
SPUU 154 26 124
DCOR 145 24 597
IE00BHXMHL11.SG 127 22 703
STXG 127 21 544
APX.PA 103 15 807
LASI.DE 103 15 807
APEX.L 103 18 047
STXV 100 16 964
BUYO 98 16 625
ONEO 86 15 227
CBUG.DE 84 12 421
EWSA.AS 84 14 199
GHYS.L 82 10 506
GHYC.SW 82 11 322
DEUS 70 12 333
SPXE 64 10 856
SPXN 63 10 687
PHDG 59 10 395
XYLG 59 10 008
GHYC.SW 58 7 951
SP5C.PA 49 7 520
LYSPH.SW 49 6 990
6TVM.DE 49 7 520
SP5G.L 49 6 506
LSPX.L 49 650 611
SP5C.L 49 8 585
SP5L.L 49 6 506
SP5H.PA 49 7 520
ETFSP500.WA 49 32 150
LYPS.DE 49 7 520
LSPU.L 49 8 585
LYP2.DE 49 7 520
SPHC.MI 49 7 520
XRMI 41 6 955
BRTR 34 5 728
GHYS.L 29 3 689
SNPV 22 3 876
MMTM 14 2 462
XTR.TO 14 2 417
XS5E.DE 7 1 080
XSPU.L 7 1 233
XSPX.L 7 93 460
XS5G.L 7 934
XSXD.L 7 1 233
D5BM.DE 7 1 080
XCLR 4 678
XTR 2 339
IGDA.L 0 168 326
P500.DE 0 3 848 919
SPXD.L 0 4 392 740
PSRF.L 0 10 840 592
SPXE.L 0 779 033
PSRW.L 0 3 029 928
SPXS.L 0 4 392 740
5ESG.DE 0 682 588
5ESE.DE 0 680 645
XLVS.L 0 652 273
EQL.TO 0 3 178 198
D500.DE 0 3 848 919
PRUS.L 0 142 716
G500.L 0 331 940 893
SPES.L 0 188 235 039
PSWD.DE 0 34 950
IE00BYML9W36.SG 0 3 848 919
SPXP.L 0 333 668 162
SPEQ.L 0 2 478 113
SPEX.L 0 188 235 039
SPXD.SW 0 4 392 740
SPEP.L 0 59 174 585
XLVP.L 0 49 546 008
IE000QF66PE6.SG 0 680 645
E500.DE 0 3 837 962
SPXS.MI 0 3 848 919
IE00B3YCGJ38.SG 0 3 848 919
PXS.TO 0 6 392
ESG.TO 0 118 641
SPED.L 0 2 478 113
6PSA.DE 0 125 048
DWSH -971 -164 720
Wiadomości dla Charles River Laboratories International, Inc.
Tytuł Treść Źródło Aktualizacja Link
Deciphering Charles River (CRL) International Revenue Trends Examine the evolution of Charles River's (CRL) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects. zacks.com 2025-02-24 12:15:29 Czytaj oryginał (ang.)
Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance On Wednesday, Charles River Laboratories International Inc CRL reported fourth-quarter 2024 revenue of $1 billion, a decrease of 1.1% year over year, beating the consensus of $983.63 million. benzinga.com 2025-02-19 18:58:08 Czytaj oryginał (ang.)
Charles River Laboratories International, Inc. (CRL) Q4 2024 Earnings Call Transcript Charles River Laboratories International, Inc. (NYSE:CRL ) Q4 2024 Earnings Call February 19, 2025 8:30 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Chair, President and Chief Executive Officer Flavia Pease - Executive Vice President and Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore Matt Sykes - Goldman Sachs Tejas Savant - Morgan Stanley Dave Windley - Jefferies Ann Hynes - Mizuho Justin Bowers - Deutsche Bank Lucas Romanski - TD Cowen Michael Ryskin - Bank of America Max Smock - William Blair Jacob Johnson - Stephens Patrick Donnelly - Citi Casey Woodring - JPMorgan Operator Ladies and gentlemen, thank you for standing by, and welcome to the Charles River Laboratories Fourth Quarter and Full Year 2024 Earnings Conference Call. This call is being recorded. seekingalpha.com 2025-02-19 17:03:11 Czytaj oryginał (ang.)
CRL Stock Up on Q4 Earnings and Revenue Beat, Margins Fall Charles River's organic revenue growth in Manufacturing Solutions is more than offset by lower revenues in the RMS and DSA segments. zacks.com 2025-02-19 16:55:16 Czytaj oryginał (ang.)
Compared to Estimates, Charles River (CRL) Q4 Earnings: A Look at Key Metrics The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2025-02-19 12:35:37 Czytaj oryginał (ang.)
Charles River Laboratories (CRL) Tops Q4 Earnings and Revenue Estimates Charles River Laboratories (CRL) came out with quarterly earnings of $2.66 per share, beating the Zacks Consensus Estimate of $2.50 per share. This compares to earnings of $2.46 per share a year ago. zacks.com 2025-02-19 11:10:35 Czytaj oryginał (ang.)
Charles River beats quarterly estimates on stable demand for drug development services Charles River Laboratories on Wednesday beat fourth-quarter profit and revenue estimates, helped by stable demand for its drug discovery and development services from biotech clients. reuters.com 2025-02-19 10:11:32 Czytaj oryginał (ang.)
Gear Up for Charles River (CRL) Q4 Earnings: Wall Street Estimates for Key Metrics Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics. zacks.com 2025-02-17 12:21:22 Czytaj oryginał (ang.)
Is Now the Right Time to Hold on to Charles River Stock? CRL's solid prospects in the DSA segment and strategic partnerships present a promising opportunity for investors. zacks.com 2025-02-14 08:51:08 Czytaj oryginał (ang.)
Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-02-12 13:06:54 Czytaj oryginał (ang.)
Charles River and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions WILMINGTON, Mass. & DUBLIN--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Deciphex focus on advancing image management solutions, while developing novel AI tools for toxicologic pathology. businesswire.com 2025-02-11 10:00:00 Czytaj oryginał (ang.)
CRL Gears Up for Q4 Earnings: Here's What You Need to Know Growth across the Manufacturing and RMS segments is likely to have contributed to Charles River's fourth-quarter revenues. zacks.com 2025-02-03 10:45:28 Czytaj oryginał (ang.)
Charles River Launches Apollo for CRADL to Boost Research, Stock Rises CRL introduces Apollo for CRADL, integrating the technology stack across its robust portfolio. zacks.com 2025-01-22 11:21:18 Czytaj oryginał (ang.)
Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River expands Apollo ecosystem, offering bespoke client experiences that enable data-driven decision making. businesswire.com 2025-01-21 10:00:00 Czytaj oryginał (ang.)
Will CRL Stock Gain From Integration of Akron Bio's CSS Product Line? Charles River and Akron Bio collaborate to boost operations by integrating CGMP materials into the Cell Therapy Platform. zacks.com 2025-01-17 09:16:08 Czytaj oryginał (ang.)
Should You Retain Charles River Stock in Your Portfolio Now? CRL's solid prospects in the RMS segment and solid financial stability create a favorable outlook for investors. zacks.com 2025-01-02 10:30:28 Czytaj oryginał (ang.)
FDA Gives CRL to J&J's BLA for Subcutaneous Rybrevant in NSCLC The FDA issues a complete response letter to JNJ's BLA seeking approval for the subcutaneous formulation of Rybrevant in EGFR-mutated non-small cell lung cancer. zacks.com 2024-12-17 11:25:40 Czytaj oryginał (ang.)
Why Is Charles River (CRL) Down 8.9% Since Last Earnings Report? Charles River (CRL) reported earnings 30 days ago. What's next for the stock? zacks.com 2024-12-09 08:49:31 Czytaj oryginał (ang.)
CRL Stock to Gain From the Global Biotech Incubator Program Launch Charles River's new initiative specifically caters to early-stage biotechnology developers. zacks.com 2024-12-06 11:06:11 Czytaj oryginał (ang.)
Charles River Introduces Global Biotech Incubator Program WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Charles River Incubator Program (CIP), specializing in supporting early-stage biotechnology companies in the discovery, development and phase-appropriate manufacturing of advanced therapies. “The Charles River Incubator Program launch, through our Global Innovation Center of Excellence, demonstrates a continued commitment to the global biotechnology industry by offeri. businesswire.com 2024-12-05 10:00:00 Czytaj oryginał (ang.)
Is it the Right Time to Hold Charles River Stock in Your Portfolio? Investors are optimistic about CRL stock due to its strong RMS prospects and inorganic growth efforts. zacks.com 2024-11-28 10:21:20 Czytaj oryginał (ang.)
Charles River (CRL) International Revenue in Focus: Trends and Expectations Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects. zacks.com 2024-11-11 12:20:49 Czytaj oryginał (ang.)
Charles River Laboratories International, Inc. (CRL) Q3 2024 Earnings Call Transcript Charles River Laboratories International, Inc. (NYSE:CRL ) Q3 2024 Earnings Conference Call November 6, 2024 9:30 AM ET Company Participants Todd Spencer - Corporate Vice President of Investor Relations James Foster - President and Chief Executive Officer Flavia Pease - Chief Financial Officer Conference Call Participants Max Smock - William Blair & Company Matthew Sykes - Goldman Sachs David Windley - Jefferies Group LLC Eric Coldwell - Robert W. Baird & Co. Justin Bowers - Deutsche Bank Dan Leonard - UBS Group AG Elizabeth Anderson - Evercore ISI Michael Ryskin - BofA Securities, Inc. Tejas Savant - Morgan Stanley Casey Woodring - JPMorgan Chase & Co. Luke Sergott - Barclays Patrick Donnelly - Citigroup Inc. Operator Please stand by, we're about to begin. seekingalpha.com 2024-11-06 20:51:02 Czytaj oryginał (ang.)
Charles River's Q3 Earnings, Revenues Beat Estimates, Margins Fall CRL's organic revenue growth in the Manufacturing Solutions and RMS segments is more than offset by lower revenues in the DSA segment. zacks.com 2024-11-06 15:01:18 Czytaj oryginał (ang.)
Charles River (CRL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com 2024-11-06 12:35:40 Czytaj oryginał (ang.)
Charles River Laboratories (CRL) Q3 Earnings and Revenues Beat Estimates Charles River Laboratories (CRL) came out with quarterly earnings of $2.59 per share, beating the Zacks Consensus Estimate of $2.43 per share. This compares to earnings of $2.72 per share a year ago. zacks.com 2024-11-06 11:10:47 Czytaj oryginał (ang.)
Charles River Laboratories raises annual profit forecast on stabilizing biotech demand Charles River Laboratories raised its full-year profit forecast after beating analysts' estimates for quarterly results as the contract research firm expects demand to stabilize from biotech clients for its drug discovery and development services. reuters.com 2024-11-06 10:30:23 Czytaj oryginał (ang.)
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy? Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2024-10-30 13:07:36 Czytaj oryginał (ang.)
Why Charles River (CRL) is Poised to Beat Earnings Estimates Again Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. zacks.com 2024-10-29 15:10:53 Czytaj oryginał (ang.)
CRL Gears Up for Q3 Earnings: Here's What You Need to Know Growth across all businesses within the Manufacturing segment is likely to have contributed to Charles River's Q3 revenues, offset by lower biopharmaceutical demand. zacks.com 2024-10-22 14:30:39 Czytaj oryginał (ang.)
CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch Charles River launches Retrogenix Non-Human Protein Library to provide early insights into how therapeutics interact with non-human protein targets in vitro. zacks.com 2024-10-18 13:55:28 Czytaj oryginał (ang.)
Charles River Launches New Retrogenix® Non-Human Protein Library WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River launches the Retrogenix® Non-Human Protein Library to support assessment of off-target binding, de-risk studies & aid model selection. businesswire.com 2024-10-17 12:00:00 Czytaj oryginał (ang.)
Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories schedules third-quarter 2024 earnings release and conference call. businesswire.com 2024-10-16 20:30:00 Czytaj oryginał (ang.)
CRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica Charles River and Lundbeck sign an agreement to use Logica to advance the discovery of novel neurological drugs. zacks.com 2024-10-10 14:10:21 Czytaj oryginał (ang.)
Operadora de Fondos Banorte Adopts Charles River's Cloud-Based Platform BOSTON--(BUSINESS WIRE)--Banorte is now live on Charles River's cloud-based Investment Management Solution. businesswire.com 2024-10-08 15:26:00 Czytaj oryginał (ang.)